Stocks Health care IMDX

NASDAQ · Health care

Insight Molecular Diagnostics Inc. (IMDX)

Insight Molecular Diagnostics Inc. brought in $1.7M of revenue over the twelve months to June 30, 2026, down 60.8% from a year earlier. It posted a net loss of $49.4M. In fiscal 2025 capital spending exceeded operating cash flow by $25.4M. At June 30, 2026 it held $17.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

What Insight Molecular Diagnostics Inc. does

Insight Molecular Diagnostics Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker IMDX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where IMDX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Insight Molecular Diagnostics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 21, 2026
   Material agreement 8-K
2. August 10, 2026
   Quarterly report 10-Q · period to June 30, 2026
3. August 10, 2026
   Quarterly results 8-K
4. July 24, 2026
   Employee stock plan registration S-8
5. June 17, 2026
   Executive or director change 8-K
6. May 13, 2026
   Quarterly report 10-Q · period to March 31, 2026
7. May 13, 2026
   Quarterly results 8-K
8. May 13, 2026
   Other event 8-K/A
9. April 30, 2026
   Annual report to shareholders ARS
10. April 30, 2026
    Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 6, 2026. Insider transactions on SEC

Insider trades

What the people running Insight Molecular Diagnostics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about IMDX

What does Insight Molecular Diagnostics Inc. do?

Insight Molecular Diagnostics Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker IMDX.

Is Insight Molecular Diagnostics Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $49.4M on revenue of $1.7M.

How much revenue does Insight Molecular Diagnostics Inc. make?

Over the twelve months to June 30, 2026 Insight Molecular Diagnostics Inc. reported revenue of $1.7M. That is 60.8% less than a year earlier.

When did Insight Molecular Diagnostics Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 21, 2026.

Similar companies

Compare IMDX with

Compare IMDX with any company

Follow IMDX

Get an email when Insight Molecular Diagnostics Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IMDX: get an email when it files

Where the numbers come from

Financial figures are the values Insight Molecular Diagnostics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.